XML 41 R26.htm IDEA: XBRL DOCUMENT v3.22.0.1
Share-based compensation
 12 Months Ended
Dec. 31, 2021
Disclosure Of Share Based Payments [Abstract]  
Share-based compensation Share-based compensation
Stock Option Plans
During 2020 and 2021, the Company implemented new Employee Stock Option Plans ("ESOP") and Director Stock Option Plans (together, the "Stock Options Plans"). Under the Stock Option Plans, stock options of the Company are granted to certain employees of the Group and members of its board of directors. For options granted under the Stock Option Plans, the exercise price is equal to the fair value of the ordinary shares on grant date or equal to 150% of the fair value of the ordinary shares on grant date. The exercise price is included in the grant date fair value of the award. The exercise price for options is payable in the EUR value of a fixed USD amount; therefore, the Group considers these options to be USD-denominated. The options granted to participants under the Stock Option Plans have a first vesting period of three or eight months from date of grant and vest monthly or annually thereafter until fully vested. The options are granted with a term of five years.
Restricted Stock Unit Program
During 2020 and 2021, the Company implemented new restricted stock unit (“RSU”) programs for employees and for members of its board of directors (together, the "RSU Plans”). The RSU Plans are accounted for as equity-settled share-based compensation transactions. The RSUs are measured based on the fair market value of the underlying ordinary shares on the date of grant. The RSUs granted to participants under the RSU Plans have a first vesting period of three or eight months from date of grant and vest monthly or annually thereafter until fully vested four years from date of grant. The valuation of the RSUs was consistent with the fair value of the ordinary shares.
Restricted Stock Awards and Other
In connection with an acquisition during 2017, the Group issued 61,880 restricted stock awards (“RSAs”) to certain employees of the acquiree. Vesting of the RSAs is contingent on continued employment of these employees. The awards are accounted for as equity-settled share-based compensation transactions. The RSAs vest over a two- and three-year period from the acquisition date. The valuation of the RSAs was consistent with the fair value of the ordinary shares. As of December 31, 2020, there are no longer any RSAs outstanding.
In connection with the acquisition of Anchor during 2019 and The Ringer during 2020, the Company granted 162,320 and 34,450 equity instruments to certain employees of Anchor and The Ringer, respectively. Each instrument effectively represents one ordinary share of the Company, which will be issued to the holder upon vesting. The instruments vest annually over a four-year and five-year period, respectively, from the acquisition date, and vesting of the instruments is contingent on continued employment. The instruments are accounted for as equity-settled share-based compensation transactions and are measured based on the fair market value of the underlying ordinary shares on the date of grant. The grant date fair value of each equity instrument granted to certain employees of Anchor and The Ringer was US$145.21 and US$145.14, respectively.
Activity in the Group's RSUs, RSAs, and other contingently issuable shares outstanding and related information is as follows:
RSUsRSAsOther
Number of
RSUs		Weighted
average
grant date
fair value		Number of
Awards		Weighted
average
grant date
fair value		Number of
Awards		Weighted
average
grant date
fair value
US$US$US$
Outstanding at January 1, 2019100,383 63.87 61,880 90.65 — — 
Granted715,224 137.15 — — 162,320 145.21 
Forfeited(48,754)118.96 — — — — 
Released(128,503)98.52 (20,600)90.65 — — 
Outstanding at December 31, 2019638,350 134.79 41,280 90.65 162,320 145.21 
Granted1,127,149 161.50 — — 34,450 145.14 
Forfeited(91,613)143.13 — — — — 
Released(353,693)138.66 (41,280)90.65 (40,580)145.21 
Outstanding at December 31, 20201,320,193 155.98 — — 156,190 145.19 
Granted793,337 277.21 — — 22,988 261.00 
Forfeited(175,751)190.26 — — — — 
Released(512,583)178.19 — — (70,458)182.98 
Outstanding at December 31, 20211,425,196 211.25 — — 108,720 145.19 
In the table above, the number of RSUs released include ordinary shares that the Group has withheld for settlement of employees’ tax obligations due upon the vesting of RSUs.
Activity in the stock options outstanding and related information is as follows:
Options
Number of
options		Weighted
average
exercise price
US$
Outstanding at January 1, 201912,243,526 77.63 
Granted4,152,565 147.11 
Forfeited(719,860)105.01 
Exercised(3,478,660)49.41 
Expired(43,799)117.79 
Outstanding at December 31, 201912,153,772 107.68 
Granted2,356,040 180.12 
Forfeited(855,051)131.30 
Exercised(4,556,908)78.87 
Expired(56,565)146.69 
Outstanding at December 31, 20209,041,288 138.60 
Granted2,164,070 315.86 
Forfeited(414,317)191.43 
Exercised(2,074,572)96.12 
Expired(21,121)196.25 
Outstanding at December 31, 20218,695,348 190.19 
Exercisable at December 31, 20195,553,650 84.18 
Exercisable at December 31, 20204,022,751 113.91 
Exercisable at December 31, 20214,453,983 152.64 
The weighted-average contractual life for the stock options outstanding at December 31, 2021, 2020, and 2019 is 2.7 years, 2.9 years, and 2.9 years, respectively. The weighted-average share price at exercise for options exercised during 2021, 2020, and 2019 was US$280.08, US$198.10, and US$141.82, respectively. The weighted-average fair value of options granted during the year ended at December 31, 2021, 2020, and 2019 was US$78.65 per option, US$36.82 per option, and US$34.63 per option, and, respectively.
The stock options outstanding at December 31, 2021, 2020, and 2019 are comprised of the following:
202120202019
Range of exercise prices (US$)Number of
options		Weighted
average
remaining
contractual
life (years)		Number of
options		Weighted
average
remaining
contractual
life (years)		Number of
options		Weighted
average
remaining
contractual
life (years)
1.65to45.003,533 1.8195,207 0.32,130,161 0.9
45.01to90.00415,340 0.21,243,833 1.22,482,270 2.2
90.01to135.001,659,359 1.82,234,257 2.72,946,838 3.4
135.01to180.003,076,253 2.53,671,417 3.53,318,423 4.1
180.01to498.983,540,863 3.71,696,574 3.61,276,080 3.7
8,695,348 2.79,041,288 2.912,153,772 2.9
In determining the fair value of the stock options, the Group uses the Black-Scholes option-pricing model. The Company does not anticipate paying any cash dividends in the near future and therefore uses an expected dividend yield of zero in the option valuation model. The expected volatility is based on the historical volatility of public companies that are comparable to the Group over the expected term of the award. The risk-free rate is based on U.S. Treasury zero-coupon rates as the exercise price is based on a fixed USD amount. The expected life of the stock options is based on historical data and current expectations.
The following table lists the inputs to the Black-Scholes option-pricing models used for stock options for the years ended December 31, 2021, 2020, and 2019:
202120202019
Expected volatility (%)
34.1 – 43.1
30.0 – 42.8
30.1 – 35.2
Risk-free interest rate (%)
0.2 – 1.1
0.1 – 1.7
1.4 – 2.6
Expected life of stock options (years)
2.6 – 4.8
2.6 – 4.8
2.5 – 4.8
Weighted-average share price (US$)283.15 162.82 136.09 
Valuation assumptions are determined at each grant date and, as a result, are likely to change for share-based awards granted in future periods. Changes to the input assumptions could materially affect the estimated fair value of share-based compensation awards.
The sensitivity analysis below shows the impact of increasing and decreasing expected volatility by 10% as well as the impact of increasing and decreasing the expected life by one year. This analysis was performed on stock options granted in 2021. The following table shows the impact of these changes on stock option expense for the options granted in 2021:
2021
(in € millions)
Actual stock option expense56 
Stock option expense increase/(decrease) under the following
   assumption changes
Volatility decreased by 10%(13)
Volatility increase by 10%16 
Expected life decrease by 1 year(8)
Expected life increase by 1 year9 
The expense recognized in the consolidated statement of operations for share-based compensation is as follows:
202120202019
(in € millions)
Cost of revenue9 8 4 
Research and development119 84 61 
Sales and marketing41 34 27 
General and administrative54 50 30 
Total223 176 122